Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 12/22/14 → 09/13/18 |
Funding
- Cell Therapeutics Inc: $64,647.00
A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
- Lan, Fengshuo (PI)
- Gabig, Theodore (CoPI)
- Kiner-Strachan, Bonnie (CoPI)
Project: Research